WO2001046209A1 - Sondes fluorescentes - Google Patents
Sondes fluorescentes Download PDFInfo
- Publication number
- WO2001046209A1 WO2001046209A1 PCT/US2000/034714 US0034714W WO0146209A1 WO 2001046209 A1 WO2001046209 A1 WO 2001046209A1 US 0034714 W US0034714 W US 0034714W WO 0146209 A1 WO0146209 A1 WO 0146209A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- complex
- probes
- fluorescence
- lifetime
- probe
- Prior art date
Links
- 239000007850 fluorescent dye Substances 0.000 title description 4
- 238000003556 assay Methods 0.000 claims abstract description 15
- 239000003446 ligand Substances 0.000 claims abstract description 14
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims abstract description 9
- 229910052751 metal Inorganic materials 0.000 claims abstract description 6
- 239000002184 metal Substances 0.000 claims abstract description 6
- 239000012620 biological material Substances 0.000 claims description 3
- 229910052723 transition metal Inorganic materials 0.000 claims description 3
- 150000003624 transition metals Chemical class 0.000 claims description 3
- 239000000523 sample Substances 0.000 description 40
- 238000002875 fluorescence polarization Methods 0.000 description 15
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 14
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 12
- 230000010287 polarization Effects 0.000 description 10
- 239000000975 dye Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 7
- 239000012491 analyte Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000001506 fluorescence spectroscopy Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical class [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 238000006862 quantum yield reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YKWAWOTVGKMRAN-UHFFFAOYSA-L 2-(4-carboxylatopyridin-2-yl)pyridine-4-carboxylate;2-pyridin-2-ylpyridine;ruthenium(2+) Chemical compound [Ru+2].N1=CC=CC=C1C1=CC=CC=N1.N1=CC=CC=C1C1=CC=CC=N1.[O-]C(=O)C1=CC=NC(C=2N=CC=C(C=2)C([O-])=O)=C1 YKWAWOTVGKMRAN-UHFFFAOYSA-L 0.000 description 1
- 239000012327 Ruthenium complex Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002601 lanthanoid compounds Chemical class 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- -1 ruthenium (II) metal complex Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage
Definitions
- This invention relates generally to fluorescencent materials and to their use in fluorescence lmmunoassavs and more particularly to the use of such materials in fluorescence resonance energy transfer (FRET) based assays and in fluorescence polarization (FP) based lmmunoassavs.
- FRET fluorescence resonance energy transfer
- FP fluorescence polarization
- metal compounds that are fluorescent and also have relatively long fluorescence lifetimes (more than 30 ns)
- One type includes lanthanide chelate compounds, and other type includes transition metal complexes.
- the lanthanide compounds have good emission, but they do not show polarized emission and, thus, are not useful as polarization probes.
- Transition metal complexes show polarized emission and , thus. have potential application as polarization probes as demonstrated recently by Lakowicz.. J. R. et. al; " Recent Development in Fluorescence Spectroscopy. Near Infrared Dyes for High Technology Application. " Edited by Daehne et. al. (eds.) 1998. Kluwer Academic Publishers, page 3-19.
- the emission lifetimes of these probes are relatively long, in most cases more than 30 ns and in some cases extending up to microseconds. Because emission is due to metal to gand charge transfer (MLCT) in these compounds, delayed emission occurs resulting in longer lifetimes.
- MLCT metal to gand charge transfer
- the long lifetime probes make possible new, improved and low cost methods for doing optical sensing using phase modulation and frequency modulation analysis as is described m US Patent 5,281.825. dated Jun. 25, 1994.
- Lakowicz. J. R., et. rr/j There are several examples of the ruthenium metal complexes as shown by Juris, A. et.al..
- the selection of the probe is depending upon the size of the analyt. For example, if one wishes to measure larger molecule, such as a large protein, one needs a longer lifetime probe Normally, the larger the protein molecule to be detected in an assay, the longer the desired fluorescence lifetime of the probe. When FP is used as the assay method, a higher value of amsotropy is needed. A useful probe should have 0 3 or higher value of amsotropy.
- the new invented FP dye is a good to study molecule having molecular weight 10 '-10° range
- a major problem for commercial success in using fluorescence techniques for lmmunoassavs with conventional probes is that their relatively short lifetimes make their use in assays for larger bio-molecules commercially unattractive because of the relatively expensive high frequency instrumentation needed to measure short fluorescent lifetimes.
- a further problem with conventional probes is photostabi ty. Many of the conventional dyes decomposes on exposure to high intensity light, creating errors m assays and also creating problems with analysis where longer exposing time is required.
- Another problem is that, there are very limited number of long lifetime FP probes available, due to that the FP based immunoassav are limited for very low molecular weight antigen.
- the mam object of the present invention is to circumvent problems described above.
- the present invention which relates to a fluorescent metal ligand complex having ligands that are capable of attachment to a biomolecule and that have an asymet ⁇ c charge state, the complex being capable of emitting polarized radiation of a sufficient lifetime to be useful in FP assavs with large molecules and as a donor in FRET assays.
- the present invention provides a probe based on a new ruthenium complex for use in
- FP lmmunoassavs as well as FRET based assays. As shown below, it provides a 35%, improvement in quantum yield, a 70%) improvement in lifetime values and a 50%> improvement in polarization values when compared to an existing well documented probe that is also based on a ruthenium (II) metal complex with diimme ligands.
- II ruthenium
- the present probe is also very photostable as compare to the conventional organic compound based fluorescence probes, which are widely use in fluorescence based lmmunoassavs.
- FIG. 1 is an absorption and emission spectra of the [Ru(aphen)(phen)(dpphenS)](T_ probe in aqueous solution.
- SCHEME I is the representation of the fluorescence dye [Ru(aphen)(phen)(dpphenS)]Cl_.
- the target compound fRu(phen)(aphen)(dpphenS)]Ch was synthesized in three steps In first step compound Ru(phen)C was prepared.
- the intermediate compound fRu(phen)(aphen)(dpphenS)]Ch was synthesized in three steps In first step compound Ru(phen)C was prepared.
- Ru(phen)Cl i was obtained by mixing equal molar solution of RuCh and 1, 10-phenathrolme in 3N HC1 (both chemicals were purchased from Aldnch Chemical Co. Inc.). The reaction mixture was stirred at room temperature for seven days after that black color precipitates form, which were separated bv filtration and washed with water and dried in air.
- Ru(phen)(aphen)Cl'2 was prepared.
- This intermediate, Ru(phen)(aphen)Cl2 was prepared by reaction of 5-am ⁇ no-l, 10-phenanathrol ⁇ ne (aphen) (purchased from Polysciences Inc.) with Ru(phen)Cl4 in 1.1 ratio respectively m refluxmg DMF for 24 hr.
- the black color compound was separated from reaction mixture by evaporating solvent and washed with water and dried
- the third and final step was the synthesis of [Ru(phen)(aphen)(dpphenS)lCb.
- the target compound. [Ru(phen)(aphen)(dpphenS)]Cb was prepared by reaction of Ru(phen)(aphen)Cl2 With 4 7-d ⁇ phenvld ⁇ sulphon ⁇ c acid- 1, 10-phenanthrolme (dpphenS) in 1.1 ratio respectively in refluxmg 1:1 ethanol water mixture for 24 hrs. After 24-hr. color of the reaction mixture changes from purple brown to orange red At this time the reaction mixture was brought down to room temperature and solvent was reduced to less than half and product was crystallized by adding large amount of acetone. It was further purified by passing through silica column using acetone water mixture.
- r amsotropy of the analyt.
- rn amsotropy of dye (m the absence of rotational diffusion), is lifetime of the probe and is rotational correlation time.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
L'invention se rapporte à un complexe de ligands métalliques fluorescents présentant un état de champ asymétrique . Ce complexe contient des ligands parmi lesquels un au moins peut se fixer à une biomolécule et émettre une fluorescence polarisée de durée suffisamment longue pour être utilisé en tant que fluorophore dans une analyse FP ou en tant que donneur dans une analyse FRET.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17268199P | 1999-12-20 | 1999-12-20 | |
US60/172,681 | 1999-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001046209A1 true WO2001046209A1 (fr) | 2001-06-28 |
Family
ID=22628734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/034714 WO2001046209A1 (fr) | 1999-12-20 | 2000-12-20 | Sondes fluorescentes |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2001046209A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8216582B2 (en) | 2006-06-23 | 2012-07-10 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
US8580257B2 (en) | 2008-11-03 | 2013-11-12 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of kidney associated antigen 1 (KAAG1) |
WO2014203067A1 (fr) * | 2013-06-18 | 2014-12-24 | Rubipy Scientific, Inc. | Complexes métalliques électroniquement neutres en tant que marqueurs biologiques |
US8937163B2 (en) | 2011-03-31 | 2015-01-20 | Alethia Biotherapeutics Inc. | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
CN106893108A (zh) * | 2017-02-15 | 2017-06-27 | 中国科学院福建物质结构研究所 | 一种利用可见光敏化近红外稀土发光的钌‑钕双金属配位聚合物及其制备方法和用途 |
CN108732147A (zh) * | 2018-04-23 | 2018-11-02 | 南京邮电大学 | 基于fret效应探测细胞凋亡过程的方法 |
US11084872B2 (en) | 2012-01-09 | 2021-08-10 | Adc Therapeutics Sa | Method for treating breast cancer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4745076A (en) * | 1984-09-17 | 1988-05-17 | Hoffmann-La Roche Inc. | Ruthenium complexes useful as carriers for immunologically active materials |
US5112974A (en) * | 1985-01-18 | 1992-05-12 | The Trustees Of Columbia University In The City Of New York | Mixed ligand complexes and uses thereof as binding agents to DNA |
US5278043A (en) * | 1990-01-25 | 1994-01-11 | Hoffmann-La Roche Inc. | Ruthenium-lumazine energy transfer systems |
-
2000
- 2000-12-20 WO PCT/US2000/034714 patent/WO2001046209A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4745076A (en) * | 1984-09-17 | 1988-05-17 | Hoffmann-La Roche Inc. | Ruthenium complexes useful as carriers for immunologically active materials |
US5112974A (en) * | 1985-01-18 | 1992-05-12 | The Trustees Of Columbia University In The City Of New York | Mixed ligand complexes and uses thereof as binding agents to DNA |
US5278043A (en) * | 1990-01-25 | 1994-01-11 | Hoffmann-La Roche Inc. | Ruthenium-lumazine energy transfer systems |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8216582B2 (en) | 2006-06-23 | 2012-07-10 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
US8580257B2 (en) | 2008-11-03 | 2013-11-12 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of kidney associated antigen 1 (KAAG1) |
US9855291B2 (en) | 2008-11-03 | 2018-01-02 | Adc Therapeutics Sa | Anti-kidney associated antigen 1 (KAAG1) antibodies |
US10597450B2 (en) | 2011-03-31 | 2020-03-24 | Adc Therapeutics Sa | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
US8937163B2 (en) | 2011-03-31 | 2015-01-20 | Alethia Biotherapeutics Inc. | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
US9393302B2 (en) | 2011-03-31 | 2016-07-19 | Alethia Biotherapeutics Inc. | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
US9828426B2 (en) | 2011-03-31 | 2017-11-28 | Adc Therapeutics Sa | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
US11084872B2 (en) | 2012-01-09 | 2021-08-10 | Adc Therapeutics Sa | Method for treating breast cancer |
WO2014203067A1 (fr) * | 2013-06-18 | 2014-12-24 | Rubipy Scientific, Inc. | Complexes métalliques électroniquement neutres en tant que marqueurs biologiques |
CN105492575A (zh) * | 2013-06-18 | 2016-04-13 | 联吡啶钌科学公司 | 作为生物标记物的电中性金属配合物 |
CN105492575B (zh) * | 2013-06-18 | 2019-01-22 | 联吡啶钌科学公司 | 作为生物标记物的电中性金属配合物 |
US10203333B2 (en) | 2013-06-18 | 2019-02-12 | Rubipy Scientific, Inc. | Electronically neutral metal complexes as biological labels |
CN106893108A (zh) * | 2017-02-15 | 2017-06-27 | 中国科学院福建物质结构研究所 | 一种利用可见光敏化近红外稀土发光的钌‑钕双金属配位聚合物及其制备方法和用途 |
CN106893108B (zh) * | 2017-02-15 | 2019-04-16 | 中国科学院福建物质结构研究所 | 一种利用可见光敏化近红外稀土发光的钌-钕双金属配位聚合物及其制备方法和用途 |
CN108732147A (zh) * | 2018-04-23 | 2018-11-02 | 南京邮电大学 | 基于fret效应探测细胞凋亡过程的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1078023B1 (fr) | Composes luminescents | |
Terpetschnig et al. | Synthesis of squaraine-N-hydroxysuccinimide esters and their biological application as long-wavelength fluorescent labels | |
Guo et al. | A long-lived, highly luminescent Re (I) metal–ligand complex as a biomolecular probe | |
JP5335236B2 (ja) | ランタニド・キレートと、バイオアッセイにおけるその使用 | |
US5731147A (en) | Luminescent metal chelate labels and means for detection | |
Papkovsky et al. | Emerging applications of phosphorescent metalloporphyrins | |
US5622821A (en) | Luminescent lanthanide chelates and methods of use | |
EP0580979B1 (fr) | Procédé de détection par induction d'électrochimiluminescence | |
GB2284809A (en) | A fluorescent phenylboronic acid for use in the detection of saccharides | |
JP2004352998A (ja) | 発光アリールスルホネートシアニン染料を用いた物質の標識ないし検出方法 | |
US6214628B1 (en) | Method of conducting an assay of a sample containing an analyte of interest | |
JP2883824B2 (ja) | ボロン酸基を有する発蛍光性化合物 | |
WO2003076938A1 (fr) | Nouveaux composes de marquage fluorescents | |
CA2336904A1 (fr) | Nouveaux chelates fluorescents aux lanthanides | |
CN101712637B (zh) | 标记化合物以及使用该标记化合物的检测方法 | |
US6538129B1 (en) | Luminescent compounds | |
Terpetschnig et al. | Fluorescence polarization immunoassay of a high-molecular-weight antigen using a long wavelength-absorbing and laser diode-excitable metal–ligand complex | |
WO2001046209A1 (fr) | Sondes fluorescentes | |
EP1623979A1 (fr) | Complexe de lanthanide fluorescent | |
Szmacinski et al. | Long-lifetime Ru (II) complexes for the measurement of high molecular weight protein hydrodynamics | |
US20010021514A1 (en) | Luminescent metal-ligand complexes | |
JP3538277B2 (ja) | 免疫測定用標識試薬及びそれに用いる蛍光性化合物及び錯体、及びそれらを用いる生物物質の免疫測定法 | |
WO2001032665A2 (fr) | Complexes a ligands de ruthenium metallique | |
EP1483582B1 (fr) | Dosage a amelioration de fluorescence dissociative | |
Terpetschnig et al. | Luminescent probes for NIR sensing applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |